Arlington Partners LLC Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Arlington Partners LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 249.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,128 shares of the company's stock after acquiring an additional 18,641 shares during the quarter. Johnson & Johnson makes up 1.7% of Arlington Partners LLC's holdings, making the stock its 28th largest holding. Arlington Partners LLC's holdings in Johnson & Johnson were worth $4,333,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after buying an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Johnson & Johnson by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after acquiring an additional 1,561,036 shares during the period. Northern Trust Corp raised its stake in shares of Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter worth approximately $4,390,037,000. Finally, Wellington Management Group LLP increased its holdings in Johnson & Johnson by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

JNJ has been the subject of several research reports. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Barclays cut their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Trading Down 0.0%

Shares of NYSE:JNJ opened at $152.25 on Friday. The business's 50-day moving average is $153.85 and its 200 day moving average is $153.69. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market capitalization of $366.33 billion, a P/E ratio of 16.94, a P/E/G ratio of 2.31 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.42%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.